Definium Therapeutics (DFTX) Earnings Analysis

Definium Therapeutics (DFTX) next reports earnings on 2026-07-30, consensus EPS -0.55 USD. Last quarter (2026-02-26) it missed with EPS -0.51 USD vs -0.48368 USD est (-5.4%). It has beaten estimates in 1/5 recent quarters (20%). Trailing P/E -17.47.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does DFTX next report earnings?

Next earnings date2026-07-30
Consensus EPS estimate-0.55 USD
Revenue estimaten/a

DFTX earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-02-26-0.51 USD-0.48368 USD-5.4%Miss
2025-11-06-0.78 USD-0.52 USD-50%Miss
2025-07-31-0.5 USD-0.38 USD-31.6%Miss
2025-05-08-0.35 USD-0.36 USD+2.8%Beat
2025-03-06-0.41 USD-0.33 USD-24.2%Miss

Beat rate: 1/5 (20%) over reported quarters with consensus data.

DFTX valuation and analyst view

Trailing P/E-17.47
Trailing EPS-2.18348 USD
Price / book17.04
Dividend yield0.00%
Market cap4.77B
Analyst consensusBuy (10 buy / 0 hold / 0 sell)
Avg price target55.43 USD

Related research pages

Frequently asked questions

When is Definium Therapeutics (DFTX)'s next earnings date?

Definium Therapeutics is next scheduled to report on 2026-07-30, with a consensus EPS estimate of -0.55 USD.

Did DFTX beat earnings last quarter?

In its 2026-02-26 report, DFTX posted EPS of -0.51 USD versus a -0.48368 USD estimate — a miss of 5.4%.

What is DFTX's earnings track record?

Over the last 5 reported quarters with consensus data, DFTX beat estimates 1 times (20%).

What is DFTX's current P/E ratio and EPS?

DFTX trades at a trailing P/E of -17.47 on trailing EPS of -2.1834814352786966 USD.

What do analysts rate DFTX?

Analyst consensus is "Buy" across 10 ratings (0 strong buy, 10 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 55.43 USD.